Lokivetmab (Cytopoint) Deep Dive: How Monoclonal Antibodies Stop Dog Itch

Based on peer reviewed veterinary research · For educational purposes only · Updated October 2026 · 9 min read

What Is Lokivetmab (Cytopoint)?

Lokivetmab is a caninized monoclonal antibody that binds and neutralises canine interleukin-31 (IL-31), the principal cytokine responsible for itch signalling in canine atopic dermatitis, delivered as a single subcutaneous injection that provides relief for approximately one month. It was conditionally licensed in the United States in 2016 and marketed by Zoetis as Cytopoint.

The word caninized is doing real work in that sentence. The antibody was originally raised in mice, then engineered so that more than 90% of its amino acid sequence is canine, with only the antigen-binding regions retaining murine-derived structure. This matters because a foreign protein injected repeatedly into a dog would ordinarily provoke anti-drug antibodies that neutralise it. Caninization keeps that risk low enough for indefinite monthly dosing.

The distinction from every oral itch therapy is categorical. Small-molecule drugs act inside cells, crossing membranes to inhibit an enzyme or bind a receptor, and they are metabolised by the liver and excreted by the kidneys. Monoclonal antibodies act outside cells, circulating in plasma and interstitial fluid and binding their target like a sponge. Lokivetmab is a protein, so it is degraded into amino acids by the same catabolic machinery that recycles the dog's own immunoglobulins. It does not pass through cytochrome P450, which is why it carries no known drug interactions and requires no liver or kidney bloodwork.

That pharmacological profile makes it particularly relevant to geriatric patients, dogs with concurrent hepatic or renal disease, and dogs already on multiple medications, where adding another hepatically metabolised drug is undesirable.

How Do Monoclonal Antibodies Stop Itch at the Molecular Level?

Itch in canine atopic dermatitis follows a defined relay. Allergen exposure activates Th2 lymphocytes, those lymphocytes secrete IL-31, IL-31 binds a heterodimeric receptor (IL-31RA paired with oncostatin M receptor beta) on sensory neurons in the dorsal root ganglia, the receptor's associated Janus kinases fire, and the neuron transmits an itch signal to the spinal cord and brain. The dog scratches, the scratching damages the epidermal barrier, more allergen penetrates, and the cycle tightens.

Lokivetmab intervenes at the earliest possible point. It binds free IL-31 in circulation with high affinity and sterically blocks the binding site the cytokine needs to engage IL-31RA. The neuron is never stimulated, so no signal is generated. Gonzales and colleagues confirmed in 2016 that lokivetmab abolished pruritic behaviour in dogs given recombinant canine IL-31, establishing the mechanism directly.

Contrast this with JAK inhibition. Oclacitinib lets IL-31 bind its receptor and then blocks the intracellular kinase that relays the message, which also blocks JAK1-dependent signalling for IL-2, IL-4, IL-6 and IL-13. Lokivetmab removes the ligand before binding and touches nothing else. The clinical consequence is a narrower therapeutic footprint: highly specific itch control, but no effect on the broader Th2 inflammatory cascade.

How Long Does One Cytopoint Injection Last?

The labelled dose is a minimum of 1 mg/kg administered subcutaneously, supplied in fixed vial strengths so that most dogs receive somewhat more than the minimum. Onset of pruritus relief occurs within 24 hours in the majority of responders, and duration is commonly cited as 4 to 8 weeks, with a mean elimination half-life of approximately 16 days.

In the pivotal placebo-controlled field study reported by Michels and colleagues, a single injection produced a significant reduction in owner-assessed pruritus visual analogue scores relative to placebo, with response maintained across the dosing interval in most treated dogs. Real-world duration varies considerably. Some dogs need redosing at 4 weeks, others hold comfortably at 8, and the practical approach is to record the day itch returns and set the next injection interval from that observation rather than from a fixed calendar.

Safety has been consistently favourable. Adverse events reported in field studies were uncommon and largely limited to transient injection-site discomfort, lethargy and occasional vomiting, with incidence broadly comparable to placebo. Because lokivetmab does not suppress broad immune function, it has not been associated with the demodicosis and dermatophytosis signal seen in long-term JAK inhibitor safety data.

The realistic failure rate deserves honest framing. Roughly 20 to 25% of atopic dogs respond inadequately. Non-response is usually not a failure of the antibody, it is evidence that something other than IL-31 is generating the itch.

Why Does Cytopoint Sometimes Not Work?

When a dog on lokivetmab keeps scratching, the differential is short and mostly actionable.

Secondary infection is the single most common explanation. Staphylococcus pseudintermedius and Malassezia pachydermatis overgrow readily on inflamed atopic skin, and both are directly pruritogenic through pathways entirely independent of IL-31. Bacterial superantigens and yeast-derived proteases stimulate sensory nerves and inflammatory cells regardless of how thoroughly IL-31 has been neutralised. A dog with active pyoderma will itch through any IL-31 blockade.

Flea allergy dermatitis is driven by salivary antigen and a distinct hypersensitivity cascade. A single flea bite can sustain weeks of pruritus in a sensitised dog, which is why year-round prevention is non-negotiable, as covered in our flea allergy dermatitis reference.

Food-responsive dermatosis can present identically to environmental atopy and requires a strict 8 to 12 week elimination diet trial to identify. Sarcoptic mange produces intense pruritus through mite burrowing and mechanical irritation, not cytokine signalling, and is frequently missed because skin scrapings are negative in a substantial proportion of genuinely infested dogs. Behavioural licking in chronically pruritic dogs can persist as a learned habit after the original inflammatory trigger has resolved.

Sorting these apart is a clinical exercise, but the visual patterns differ meaningfully. The Dog Skin Condition Checker is built for exactly this triage step, and the recurring-flare pattern is examined in why some dogs keep getting skin infections.

Pairing Biologic Itch Control With Topical Antimicrobial Care

Lokivetmab's precision is its strength and its boundary. Neutralising one cytokine is elegant, but it leaves the skin surface exactly as colonised as it was before the injection, and on atopic skin that surface is rarely sterile. Barrier dysfunction, elevated surface pH and increased corneocyte adherence all favour staphylococcal and Malassezia overgrowth, and that overgrowth generates itch the antibody cannot reach.

Topical antimicrobial therapy addresses this directly and, importantly, adds no systemic burden to a biologic protocol chosen precisely for its clean pharmacokinetics. Chlorhexidine gluconate is a cationic bisbiguanide that binds the anionic bacterial cell envelope, disrupts membrane integrity and precipitates cytoplasmic contents, giving rapid bactericidal activity against S. pseudintermedius including meticillin-resistant isolates, with residual substantivity that keeps working on the stratum corneum after rinsing. Ketoconazole inhibits lanosterol 14-alpha-demethylase, the fungal enzyme that converts lanosterol into ergosterol, so Malassezia cannot construct a functional cell membrane.

Vetified Chlorhexidine Shampoo contains chlorhexidine gluconatewith ketoconazole, covering both organisms in a single bath. It is an FDA-registered over-the-counter veterinary drug listed on DailyMed rather than a cosmetic grooming product, which means the actives are present at declared, quantified concentrations. Clinical use typically involves approximately 10 minutes of contact time before rinsing, twice weekly during active infection, tapering to weekly or fortnightly maintenance once lesions resolve.

There is a strategic argument beyond symptom control. Topical antimicrobials reach the skin surface at concentrations systemic antibiotics cannot achieve, which is why veterinary dermatology consensus guidance now positions topical therapy as first-line for surface and superficial pyoderma, reserving systemic antibiotics for deeper or refractory disease. Given rising meticillin resistance in S. pseudintermedius, that shift is a meaningful piece of antimicrobial stewardship. Further background is available in our chlorhexidine reference for dogs and our guide to choosing a shampoo for itchy allergic skin.

Where Lokivetmab Fits in Long-Term Atopy Management

The International Committee on Allergic Diseases of Animals frames atopic dermatitis management as four parallel tracks rather than a single drug decision: control flare factors, improve skin hygiene and barrier function, reduce pruritus pharmacologically, and address the underlying sensitisation with allergen-specific immunotherapy.

Lokivetmab is a strong fit for the third track in specific situations. It suits dogs whose owners cannot reliably administer twice-daily oral medication, dogs with concurrent hepatic or renal disease where additional metabolised drugs are unwelcome, dogs under 12 months of age that fall outside the oclacitinib label, and dogs with seasonal flares where a handful of injections covers the pollen window. It is less suited to dogs needing same-day relief before an injection can be scheduled, and it is more expensive per month than generic oral options in most markets.

Immunotherapy remains the only intervention that modifies the disease rather than its output, with reported response rates of approximately 50 to 80% in appropriately selected patients, though clinical benefit generally takes 6 to 12 months to appear. Lokivetmab is well suited to bridging that interval, keeping the dog comfortable while immunotherapy builds tolerance.

Prevention work continues regardless of which itch therapy is chosen: year-round parasite control, routine bathing to reduce allergen and microbial load on the coat, prompt attention to ear discharge before otitis becomes chronic, and periodic reassessment of the diagnosis itself. The broader plan is laid out in our long-term itch management strategy and our complete atopic dermatitis guide.

Frequently Asked Questions

How long does a Cytopoint injection last in dogs?

Most dogs get 4 to 8 weeks of pruritus control from a single subcutaneous injection dosed at a minimum of 1 mg/kg, with relief usually beginning within 24 hours. The mean elimination half-life is approximately 16 days, and the practical approach is to note the day itching returns and set the next injection interval from that observation.

Is Cytopoint safer than Apoquel?

They carry different risk profiles rather than a simple safety ranking. Lokivetmab targets one cytokine and is cleared by protein catabolism, so it has no known drug interactions and requires no liver or kidney monitoring, and it has not shown the demodicosis and dermatophytosis signal reported in long-term oclacitinib safety data. Oclacitinib offers faster onset and oral flexibility. The right choice depends on the individual dog's age, concurrent disease and flare pattern.

Can Cytopoint and Apoquel be used together?

Some veterinary dermatologists do combine them in refractory cases, since they act at different points in the same pathway, one neutralising IL-31 extracellularly and the other blocking JAK1 inside the cell. This is an off-label strategy that should only be undertaken under direct veterinary supervision, and persistent itch on either drug warrants a search for infection or another non-IL-31 driver first.

Does Cytopoint treat skin infections in dogs?

No. Lokivetmab has no antimicrobial activity whatsoever. It neutralises interleukin-31 and nothing else, so bacterial pyoderma and Malassezia dermatitis continue unchanged and continue generating itch through separate pathways. Topical antibacterial and antifungal therapy, such as a chlorhexidine gluconate and ketoconazole shampoo, remains necessary alongside it.

Sources

1. Michels GM, Ramsey DS, Walsh KF, et al. A blinded, randomized, placebo-controlled, dose determination trial of lokivetmab (ZTS-00103289), a caninized, anti-canine IL-31 monoclonal antibody in client owned dogs with atopic dermatitis. Veterinary Dermatology. 2016;27(6):478-e129.
2. Gonzales AJ, Fleck TJ, Humphrey WR, et al. IL-31-induced pruritus in dogs: a novel experimental model to evaluate anti-pruritic effects of canine therapeutics. Veterinary Dermatology. 2016;27(1):34-e10.
3. Souza CP, Rosychuk RAW, Contreras ET, et al. A retrospective analysis of the use of lokivetmab in the management of allergic pruritus in a referral population of 135 dogs in the western USA. Veterinary Dermatology. 2018;29(6):489-e164.
4. Olivry T, DeBoer DJ, Favrot C, et al. Treatment of canine atopic dermatitis: 2015 updated guidelines from the International Committee on Allergic Diseases of Animals. BMC Veterinary Research. 2015;11:210.
5. Hillier A, Lloyd DH, Weese JS, et al. Guidelines for the diagnosis and antimicrobial therapy of canine superficial bacterial folliculitis. Veterinary Dermatology. 2014;25(3):163-e43.

Related Reading

• How JAK Inhibitors Work in Dogs: The Science Behind Apoquel (Oclacitinib)
• Canine Atopic Dermatitis: Complete Guide to Environmental Allergies
• Managing Chronic Itching in Dogs: A Long-Term Strategy Guide

E. Maddens

Founder of Vetified. Develops topical antifungal and antimicrobial formulations for companion animals. Vetified products are listed on DailyMed and manufactured through FDA-registered facilities in the United States.

Research basis: All Vetified content references peer reviewed research published in journals including Veterinary Dermatology, JAVMA, and Journal of Small Animal Practice.